期刊文献+

三种放射治疗技术治疗恶性肿瘤椎体转移的研究

Investigation of three modalities of radiotherapeutic technique for metastatic spinal lesions
原文传递
导出
摘要 目的比较三种放射治疗技术治疗椎体转移瘤的剂量学差异,提高肿瘤椎体转移的治疗效益。方法选取10例恶性肿瘤椎体转移患者,应用三维治疗计划系统分别为每例患者设计三种治疗计划:常规放射治疗(CRT)、适形放射治疗(3D-CRT)和调强放射治疗(IMRT),评估和比较各计划靶区剂量分布及危及器官剂量学参数的差异,在保证靶区治疗剂量和重要器官耐受的基础上采用调强放射治疗,并观察治疗效果和不良反应。结果 IMRT和3D-CRT对比CRT能显著提高靶区的适形度(CI),3D-CRT较IMRT能明显提高靶区剂量的均匀性(HI),IMRT在保护心脏、脊髓、食管方面明显优于其他两种技术。10例患者通过调强放射治疗后止痛有效率达100%。结论在预期生存时间较长的恶性肿瘤椎体转移患者中,应用调强放射治疗能明显减少重要器官受照的最大剂量,可望提高生活质量。 Objective To compare the difference of the three modalities of radiotherapeutic technique for metastatic spinal lesions.Methods Ten patients with vertebral metastatic cancer were designed conventional radiation therapy(CRT) plan,3-Dimensional conformal radiation therapy(3DCRT) plan and intensity modulated radiation therapy(IMRT) plan through treatment planning system(TPS).Evaluate the difference of dosimetric parameters between targetarea and criticalorgan.Then patients were treated with IMR.Results The coverage index(CI) of IMRT and 3DCRT plan were better than that of CRT plan.The relative dose homogeneity index(HI) of 3DCRT plan was better than that of the IMRT plan.The IMRT could better protect the heart,spine and esophagus than the others.The effective rate of relieving pain of ten patients was 100% by applying IMRT.Conclusions Utilizing intensity modulated radiation therapy in the expected long-term survival of patients diagnosed with vertebral metastatic can help us to reduce the maximum radiation dose of surrounding normal organs.
出处 《中国肿瘤临床与康复》 2013年第5期434-436,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 椎体转移瘤 放射治疗 三维适形放疗 调强放射治疗 Spinal metastatic Conventional radiotherapy Three-dimensional conformal radiotherapy Intensity modulated
作者简介 卢奕宇,男,主治医师,主要从事肿瘤专业。
  • 相关文献

参考文献10

  • 1周江云.单纯放疗与放疗联用唑来膦酸治疗骨转移癌疗效比较[J].现代肿瘤医学,2012,20(8):1693-1694. 被引量:7
  • 2邵倩,李建彬,田世禹,梁超前.低分割放射治疗椎体转移癌的临床观察[J].中华肿瘤防治杂志,2006,13(16):1279-1280. 被引量:2
  • 3Sciubba DM, Gokaslan ZL. Diagnosis and management of meta- static spine disease [ ] ]. Surgical Oncology, 2006, 15: 141-151.
  • 4Abrahm JL, Banffy MB, Harris MB, et al. Spinal cord compres- sion in patients with advanced metastatic cancer [ J ]. JAMA, 2008, 29 : 9937-946.
  • 5Rieden K, Adolph J, Lellig U, et al. The radiotherapeutic effect on bone metastases in relation to the frequency of metastases, sites of metastases and histology of the primary tumor [ J ]. Strahlenther Onkol, 1989, 165: 380-385.
  • 6Delank KS, Wendtner C, Eich HT, et al. The treatment of spi- nal metastases[J]. Dtsch Arztebl Int, 2011, 108:71-80.
  • 7Veldeman L, Madani I, Hulstaert F, et al. Evidence behind use of intensity-modulated radiotherapy : a systematic review of com- parative clinical studies[ J]. Lancet Oncol, 2008, 9:367-375.
  • 8任骅,高黎.鼻咽癌骨转移的发生及预后因素分析[J].中国骨肿瘤骨病,2004,3(4):208-211. 被引量:7
  • 9依荷芭丽.迟,许鸿雁,孟光丽,刘俊宝,王金万.乳腺癌骨转移患者生存分析[J].肿瘤研究与临床,2005,17(4):255-256. 被引量:2
  • 10Bilsky MH, Yamada Y, Yenice KM, et al. Intensity-modula- ted stereotactie radiotherapy of paraspinal tumors : a preliminary report [ J ]. Neurosurgery, 2004, 54 : 823-831.

二级参考文献33

  • 1[2]Huang CJ,Leung SW,Lian SL,et al. Patterns of distant metastases in nasopharyngeal carcinoma. Kaohsiung J Med Sci , 1996 , 12:229 -34.
  • 2[4]Sham JS, Choy D, Choi PH. ,et al. Nasopharyngeal carcinoma: the significance of neck node involvement in relation to the pattern of distant failure. Br J Radiol. 1990,63:108 - 13.
  • 3[5]Altun M, Fandi A, Dupos O, et al. Undifferentiated nasopharyngeal cancer(UCNT) :current diagnostic and therapeutic aspects. Int. J.Radiat. Oncol Biol Phys, 1995,32:859 - 877.
  • 4[6]Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx:a review of the Princess Margaret Hospital experience. Cancer, 1991,68:2120 - 2124.
  • 5[7]Teo PML, Kwan WH, Lee WY, et al. Prognosticators determing survival subsequent to distant metastasis from nasopharyngeal carcinoma.Cancer, 1996,77:2423 - 2431.
  • 6[10]Sham JS, Cheung YK, Chan FL, et al. Nasopharyngeal cacinoma:pattern of skeletal metastases. Br J Radiol, 1990,63:202 -205.
  • 7Dennis A C, Barry B L. Manual of clinical oncology [M]. 4th ed.Philadelphia: Lippincott Williams & Wilkins Inc, 2000: 218-237.
  • 8Hery M, Delozier T, Ramaioli A, et al. Natural history of node-negative breast cancer: are conventional prognostic factors predictor of time to relapse?[J]. Breast, 2002, 11(5): 442-448.
  • 9Sledge G N, Neuberg D, Ingle S, et al. Phase Ⅲ trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first- line therapy for metastatic cancer: an intergroup trial[J]. J Clin Oncol, 1997, 16(Proceedings ASCO): abstract 2.
  • 10Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin to first line chemotherapy for Her- 2 overexpressing metastatic breast cancer (Her-2 +/MBC) markedly increases anti cancer activity:a randomized multinational controlled phase Ⅲ trial [J]. Proceedings ASCO, 1998 (abstract): 377.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部